Bioerg Spólka Akcyjna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Bioerg Spólka Akcyjna's earnings have been declining at an average annual rate of -30.2%, while the Biotechs industry saw earnings growing at 56.3% annually. Revenues have been declining at an average rate of 10.6% per year.

Anahtar bilgiler

-30.2%

Kazanç büyüme oranı

-30.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi56.3%
Gelir büyüme oranı-10.6%
Özkaynak getirisi-29.3%
Net Marj-22.1%
Sonraki Kazanç Güncellemesi10 Aug 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Bioerg Spólka Akcyjna's (WSE:BER) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 13
Bioerg Spólka Akcyjna's (WSE:BER) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

A Look At The Intrinsic Value Of Bioerg Spólka Akcyjna (WSE:BER)

Nov 22
A Look At The Intrinsic Value Of Bioerg Spólka Akcyjna (WSE:BER)

Gelir ve Gider Dağılımı

Bioerg Spólka Akcyjna nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

WSE:BER Gelir, gider ve kazançlar (PLN Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Dec 220000
30 Sep 221010
30 Jun 221010
31 Mar 221010
31 Dec 212010
30 Sep 215-1350
30 Jun 219-1370
31 Mar 2111-1380
31 Dec 2010-1280
30 Sep 2011180
30 Jun 2013190
31 Mar 20140100
31 Dec 19160130
30 Sep 19160120
30 Jun 1914-1120
31 Mar 1911-190
31 Dec 188-170
30 Sep 185040
30 Jun 181010
31 Mar 180000
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 160000
30 Sep 162000
30 Jun 162000
31 Mar 162000
31 Dec 152000
30 Sep 151000
30 Jun 151000
31 Mar 152000
31 Dec 142000
30 Sep 142000
30 Jun 142000
31 Mar 143010
31 Dec 132010
30 Sep 132010
30 Jun 132010
31 Mar 132010
31 Dec 122000
30 Sep 121010
30 Jun 121000

Kaliteli Kazançlar: BER is currently unprofitable.

Büyüyen Kar Marjı: BER is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BER is unprofitable, and losses have increased over the past 5 years at a rate of 30.2% per year.

Büyüme Hızlandırma: Unable to compare BER's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: BER is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Özkaynak Getirisi

Yüksek ROE: BER has a negative Return on Equity (-29.33%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin